Zhaoke Ophthalmology Limited
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People's Republic of China, South Korea, Hong Kong, and internationally. It develops various drugs that cover ophthalmic indications, including dry eye disease, myopia, presbyopia, wet age-related macular … Read more
Zhaoke Ophthalmology Limited (9FX) - Net Assets
Latest net assets as of June 2025: €1.71 Billion EUR
Based on the latest financial reports, Zhaoke Ophthalmology Limited (9FX) has net assets worth €1.71 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.07 Billion) and total liabilities (€362.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.71 Billion |
| % of Total Assets | 82.47% |
| Annual Growth Rate | -8.68% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.98 |
Zhaoke Ophthalmology Limited - Net Assets Trend (2021–2024)
This chart illustrates how Zhaoke Ophthalmology Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhaoke Ophthalmology Limited (2021–2024)
The table below shows the annual net assets of Zhaoke Ophthalmology Limited from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.90 Billion | -7.24% |
| 2023-12-31 | €2.05 Billion | -12.78% |
| 2022-12-31 | €2.35 Billion | -5.90% |
| 2021-12-31 | €2.50 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhaoke Ophthalmology Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 403475300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €5.93 Billion | 312.35% |
| Total Equity | €1.90 Billion | 100.00% |
Zhaoke Ophthalmology Limited Competitors by Market Cap
The table below lists competitors of Zhaoke Ophthalmology Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Capol International & Associates Co Ltd
SHE:002949
|
$118.69 Million |
|
DURCF
PINK:DURCF
|
$118.71 Million |
|
Varia US Properties Ltd
SW:VARN
|
$118.71 Million |
|
Maui Land & Pineapple Company Inc
NYSE:MLP
|
$118.72 Million |
|
GCL NEW ENERGY HD-0832
F:TJI
|
$118.64 Million |
|
Vishnu Chemicals Limited
NSE:VISHNU
|
$118.61 Million |
|
Hube Yangfan Holding Co Ltd
SHG:600421
|
$118.54 Million |
|
Jiangsu Jingxue Insulation
SHE:301010
|
$118.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhaoke Ophthalmology Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,048,318,000 to 1,900,077,000, a change of -148,241,000 (-7.2%).
- Net loss of 237,493,000 reduced equity.
- Other factors increased equity by 89,252,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-237.49 Million | -12.5% |
| Other Changes | €89.25 Million | +4.7% |
| Total Change | €- | -7.24% |
Book Value vs Market Value Analysis
This analysis compares Zhaoke Ophthalmology Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.60 | €0.33 | x |
| 2022-12-31 | €4.32 | €0.33 | x |
| 2023-12-31 | €3.75 | €0.33 | x |
| 2024-12-31 | €3.48 | €0.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhaoke Ophthalmology Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -342.58%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.18x
- Recent ROE (-12.50%) is above the historical average (-33.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -85.35% | 0.00% | 0.00x | 1.04x | €-2.38 Billion |
| 2022 | -17.34% | 0.00% | 0.00x | 1.09x | €-642.15 Million |
| 2023 | -18.80% | -2053.54% | 0.01x | 1.18x | €-589.87 Million |
| 2024 | -12.50% | -342.58% | 0.03x | 1.18x | €-427.50 Million |
Industry Comparison
This section compares Zhaoke Ophthalmology Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhaoke Ophthalmology Limited (9FX) | €1.71 Billion | -85.35% | 0.21x | $118.66 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |